Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
palifosfamide-tris · 2 trials · 9 indications
To assess the effect of single-agent palifosfamide-tris on QTc intervals.
To assess the pharmacokinetic profile of single-agent palifosfamide-tris.
Adverse events, vital signs, physical examination, laboratory data and concomitant medications
| Arm | Type | Description |
|---|---|---|
| Single Arm | OTHER | Single Arm, non-blinded, non-randomized |
| PaCE | EXPERIMENTAL | Palifosfamide, Carboplatin and Etoposide |
| Name | Type | Description |
|---|---|---|
| palifosfamide-tris | DRUG | palifosfamide-tris IV infusion of 150 mg/m2 on Days 1, 2 and 3 every three weeks (21 day cycle) |
| Normal Saline | DRUG | 0.9% Normal Saline 250 ml IV infusion on Cycle 1 Day -1 |
Inclusion criteria: 1. Male or female subjects, age ≥ 18 years, who have provided written informed consent prior to completing any study specific procedure. 2. Histologically or cytologically confirmed solid tumor that has progressed following available standard therapies or for which no standard t...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | Pembrolizumab, Gardasil 9 |
| Incyte Corporation | INCY | 1 | PHASE2 | Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115 |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |